• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.

作者信息

Pape Elise, Feliu Catherine, Yéléhé-Okouma Mélissa, Colling Natacha, Djerada Zoubir, Gambier Nicolas, Weryha Georges, Scala-Bertola Julien

机构信息

Department of Clinical Pharmacology and Toxicology, University Hospital of Nancy, Nancy, France.

Ingénierie Moléculaire et Physiopathologie Articulaire, UMR 7365 CNRS-UL, University of Lorraine, Vandœuvre-lès-Nancy, France.

出版信息

Oncologist. 2018 Mar;23(3):389-390. doi: 10.1634/theoncologist.2017-0426. Epub 2017 Nov 30.

DOI:10.1634/theoncologist.2017-0426
PMID:29192018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5905686/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/484e/5905686/15bacbcf3f9e/onco12326-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/484e/5905686/15bacbcf3f9e/onco12326-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/484e/5905686/15bacbcf3f9e/onco12326-fig-0001.jpg

相似文献

1
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.大剂量米托坦诱发的脑病在肾上腺皮质癌治疗中的应用
Oncologist. 2018 Mar;23(3):389-390. doi: 10.1634/theoncologist.2017-0426. Epub 2017 Nov 30.
2
Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.比较两种起始剂量米托坦方案治疗晚期肾上腺皮质癌的疗效。
J Clin Endocrinol Metab. 2013 Dec;98(12):4759-67. doi: 10.1210/jc.2013-2281. Epub 2013 Sep 20.
3
[Mitotane in the treatment of adrenal carcinoma].[米托坦治疗肾上腺皮质癌]
Duodecim. 2010;126(17):2040-6.
4
Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.米托坦诱发的亚急性皮肤型红斑狼疮
JAMA Dermatol. 2016 Jan;152(1):109-11. doi: 10.1001/jamadermatol.2015.2702.
5
Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.米托坦毒性不良反应评估中治疗监测的作用：一例报告
Therapie. 2015 Nov-Dec;70(6):545-6. doi: 10.2515/therapie/2015043. Epub 2015 Aug 4.
6
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.甲灭酸水平可预测接受根治性切除术辅助治疗后的肾上腺皮质癌患者的结局。
Eur J Endocrinol. 2013 Jul 29;169(3):263-70. doi: 10.1530/EJE-13-0242. Print 2013 Sep.
7
Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.米托坦药代动力学模型的建立：迈向肾上腺皮质癌的个体化给药
Ther Drug Monit. 2015 Feb;37(1):58-65. doi: 10.1097/FTD.0000000000000102.
8
Adjuvant mitotane in adrenocortical carcinoma.肾上腺皮质癌的辅助性米托坦治疗
N Engl J Med. 2007 Sep 20;357(12):1257-8; author reply 1259.
9
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.大剂量米托坦治疗肾上腺皮质癌：随访前 3 个月内血浆米托坦浓度的前瞻性分析。
Eur J Endocrinol. 2012 Feb;166(2):261-8. doi: 10.1530/EJE-11-0557. Epub 2011 Nov 2.
10
Adjuvant mitotane for adrenocortical cancer--a recurring controversy.肾上腺皮质癌的辅助性米托坦——一个反复出现的争议。
J Clin Endocrinol Metab. 2008 Oct;93(10):3730-2. doi: 10.1210/jc.2008-0579.

引用本文的文献

1
The effect of adjuvant mitotane therapy of the adrenocortical carcinoma on the endometrium and its clinical consequences in menstruating women. Literature review and authors' own experiences.肾上腺皮质癌辅助米托坦治疗对子宫内膜的影响及其在有月经女性中的临床后果。文献综述及作者自身经验。
Am J Cancer Res. 2024 Apr 15;14(4):1802-1814. doi: 10.62347/QKWF9884. eCollection 2024.
2
Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care.晚期肾上腺皮质癌：从症状控制到姑息治疗
Cancers (Basel). 2022 Nov 29;14(23):5901. doi: 10.3390/cancers14235901.
3
EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity.

本文引用的文献

1
Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.转移性肾上腺皮质癌中米托坦的完全缓解——旧药新用。
Oncologist. 2017 Sep;22(9):1102-1106. doi: 10.1634/theoncologist.2016-0459. Epub 2017 May 30.
2
Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.米托坦治疗肾上腺皮质癌的疗效与安全性：一项针对34例比利时患者的回顾性研究。
Ann Endocrinol (Paris). 2016 Oct;77(5):578-585. doi: 10.1016/j.ando.2016.02.005. Epub 2016 Apr 7.
3
Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old Boy.
儿童使用依托咪酯-米托坦：可逆性副作用和神经毒性的可靠证据
Discov Oncol. 2022 Apr 18;13(1):25. doi: 10.1007/s12672-022-00486-1.
4
SOAT1: A Suitable Target for Therapy in High-Grade Astrocytic Glioma?SOAT1：高级别脑胶质瘤治疗的合适靶点？
Int J Mol Sci. 2022 Mar 28;23(7):3726. doi: 10.3390/ijms23073726.
5
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.米托坦的挑战性药代动力学：一种需要新包装的老药。
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21.
6
A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring.米托坦短期低剂量治疗引起神经不良事件的病例报告：治疗药物监测的作用
Medicine (Baltimore). 2020 Oct 2;99(40):e22620. doi: 10.1097/MD.0000000000022620.
7
Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art.米托坦在肾上腺皮质癌中的作用——综述与现状
Eur Endocrinol. 2018 Sep;14(2):62-66. doi: 10.17925/EE.2018.14.2.62. Epub 2018 Sep 10.
病例报告：4岁男孩肾上腺皮质癌大剂量米托坦辅助治疗
Clin Pediatr Endocrinol. 2008;17(3):71-4. doi: 10.1297/cpe.17.71. Epub 2008 Aug 8.
4
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.血浆中 o,p'DDD、o,p'DDA 和 o,p'DDE 浓度可预测对米托坦治疗肾上腺皮质癌的肿瘤反应：一项回顾性 ENS@T 多中心研究的结果。
J Clin Endocrinol Metab. 2011 Jun;96(6):1844-51. doi: 10.1210/jc.2010-2676. Epub 2011 Apr 6.
5
The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.在积极的手术治疗和使用米托坦监测的情况下，肾上腺皮质癌的长期生存。
Endocr Relat Cancer. 2010 Feb 18;17(1):265-72. doi: 10.1677/ERC-09-0190. Print 2010 Mar.
6
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.对接受辅助治疗的肾上腺皮质癌患者米托坦毒性的前瞻性评估。
Endocr Relat Cancer. 2008 Dec;15(4):1043-53. doi: 10.1677/ERC-08-0103. Epub 2008 Sep 29.
7
Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.高剂量邻对滴滴滴快速给药可在可接受的耐受性下缩短达到治疗阈值所需的时间：初步结果
Clin Endocrinol (Oxf). 2006 Jan;64(1):110-3. doi: 10.1111/j.1365-2265.2005.02403.x.
8
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.监测血浆1,1-二氯二苯二氯乙烷（邻，对-DDD）水平对肾上腺皮质癌患者治疗的影响。
Cancer. 2001 Sep 15;92(6):1385-92. doi: 10.1002/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2.
9
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.米托坦治疗肾上腺皮质癌的最佳方案：96例连续病例的结果
Br J Cancer. 1994 May;69(5):947-51. doi: 10.1038/bjc.1994.183.